Removal of the DATA Waiver (X-Waiver) Requirement Effective Immediately: Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe buprenorphine or buprenorphine/naloxone for the treatment of opioid use disorder (OUD). All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine or buprenorphine/naloxone for OUD.
SAMHSA and the DEA are actively working on implementation of a separate provision related to training requirements for DEA registration that will become available in June 2023. SUPR will share DEA registration updates as they become available. There are no longer any annual limits on the number of patients that can be cared for by a practitioner, whereas the previous maximum was 275. Of note, there are three FDA approved medications for OUD: methadone, buprenorphine, and long-acting naltrexone- and it is standard of care for all patients with OUD to be offered medication assisted recovery.
FY23 Final Payment and Data Submission: The Illinois Department of Human Services/Division of Substance Use Prevention and Recovery (IDHS/SUPR) is issuing this gentle reminder that final FY2023 submissions for all non-Medicaid SUPR funded services are due by 5:00pm on August 7, 2023. All manual vouchers for Expense Based Grants must be submitted by 5:00pm on July 15, 2023. Please share this notification, and all those subsequent, with each applicable staff in your organization. Questions concerning this requirement can be directed to DOIT.SUPRHELP@ILLINOIS.GOV
Periodic Performance Reporting (PPR): Each SUPR grant program is required to submit a PPR on a quarterly basis that provides the organizations progress on meeting their agreed upon deliverables. As we continue to improve our reporting processes and procedures, SUPR is also planning trainings and increased access to information on quarterly reporting and why it is important. We will share additional information as it becomes available.
Please see the below Quarterly Reports Periods and Due Dates:
Q1: Reporting Period 7/1-9/30/22; DUE 10/31/22
Q2: Reporting Period 10/1-12/31/22; DUE 1/31/23
Q3: Reporting Period 1/1-3/31/23; DUE 4/30/23
Q4: Reporting Period 4/1-6/30/23; DUE 7/31/23